CAC Score Predicts MACE in Patients With Stable Chest Pain
By Elana Gotkine HealthDay Reporter
THURSDAY, March 14, 2024 -- For people with stable chest pain referred for invasive coronary angiography (ICA), the risk for major adverse cardiovascular events (MACE) is low among those with a low coronary artery calcium (CAC) score, according to a study published online March 5 in Radiology.
Federico Biavati, M.D., from the Charité–Universitätsmedizin Berlin, and colleagues examined the prognostic value of CAC scoring for MACE in 1,749 study participants with stable chest pain initially referred for ICA. Participants were randomly assigned to ICA or coronary computed tomography (CT). CAC scores from noncontrast CT scans were classified as low, intermediate, and high (scores of 0, 1 to 399, and 400 or higher).
The researchers found an increase in the prevalence of obstructive coronary artery disease at CT angiography from 4.1 to 76.1 percent in the groups with CAC score 0 and CAC score 400 or higher. Across the same groups, there was an increase from 1.7 to 46.2 percent in revascularization rates. Lower MACE risk was seen in the groups with CAC scores 0 and 1 to 399 compared with the 400 or higher group (0.5 and 1.9 percent, respectively, versus 6.8 percent; hazard ratios, 0.08 and 0.27, respectively). There was no significant difference in MACE between the sexes.
"A coronary artery calcium score of 0 showed very low risk of major adverse cardiovascular events at follow-up, and increasing scores were associated with increasing rates of obstructive coronary artery disease, revascularization, and MACE," the authors write.
Several authors disclosed ties to the pharmaceutical, medical device, and publishing industries.
Editorial (subscription or payment may be required)
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2024 HealthDay. All rights reserved.
Posted March 2024
Read this next
Mean Cost of Bringing New Drug to U.S. Market Is $879.3 Million
TUESDAY, July 2, 2024 -- The mean cost of developing a new drug for the U.S. market is estimated to be $879.3 million when both drug development failure and capital costs are...
Patient–Primary Care Provider Language Concordance Tied to Better Outcomes
TUESDAY, July 2, 2024 -- Patient-family physician language concordance is associated with a lower risk for adverse outcomes, according to a study published online June 3...
Self-Administered Gerocognitive Exam Improves Detection of Cognitive Issues in Primary Care
TUESDAY, July 2, 2024 -- A self-administered gerocognitive examination (SAGE) is easily incorporated into primary care provider (PCP) visits, and its use significantly increases...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.